The Guardian

US secures world stock of key Covid-19 drug remdesivir

1 July 2020
Sarah Boseley

https://www.theguardian.com/us-news/2020/jun/30/us-buys-up-world-stock-of-key-covid-19-drug

Online Guardian news article said, “The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.”

Anthony Fauci, as Chief Medical Advisor to the President of the USA, would have been involved in the decision making process to purchase the 500,000 doses of remdesivir for its American citizens.

That decision to purchase 500,000 doses of remdesivir was made after the ebola trials which documented a mortality rate of 53%.

The Guardian news in fact confirms remdesivir’s unacceptable drug trial results by saying, “The drug, which was trialled in the Ebola epidemic but failed to work as expected, is under patent to Gilead, which means no other company in wealthy countries can make it. The cost is around $3,200 per treatment of six doses, according to the US government statement.”

The Guardian refused to present all the facts - that remdesivir resulted in a 53% death rate in the ebola trials, and instead misled readers with a deceptive sentence that remdesivir “failed to work as expected” when in fact is caused death on a massive scale.

Further in the article Anthony Fauci said, “We are going in the wrong direction,” said Fauci. Last week the US saw a new daily record of 40,000 new coronavirus cases in one day. “I would not be surprised if we go up to 100,000 a day if this does not turn around,” he said. He could not provide an estimated death toll, but said: “It is going to be very disturbing, I guarantee you that.”

It is reasonable to conclude Anthony Fauci could “guarantee” the death toll would be “disturbing” because he was fully aware remdesivir causes death in 53% of cases, and the Trump administration purchased 500,000 doses for the American people, hence the high death toll experienced in hospitals.

CNBC

Gilead strikes deal to make remdesivir coronavirus treatment for 127 countries

Berkeley Lovelace Jr
13 May 2020

https://www.cnbc.com/2020/05/12/remdesivir-coronavirus-treatment-gilead-strikes-deal-to-make-drug-in-127-countries.html

In May 2020 CNBC reported that Gilead Sciences Inc, struck a massive deal to issue remdesivir to 127 countries plus the USA.

Gilead is the patent owner of the drug remdesivir. Remdesivir

  • was a drug rejected for use to treat ebola in November 2019 due to its mortality rate of 53%; and

  • is the drug that was selected in March 2020 to be the primary drug for use to treat covid-19 in hospitals.

The report also says, “The intravenous drug has helped shorten the recovery time of some hospitalized Covid-19 patients, new clinical trial data suggests. Without other proven treatments, physicians will likely be considering its use to treat the coronavirus.”

The news article refused to report on the documented death rates of remdesivir and presented a deceptive message of benefit from remdesivir.

Further, the report states, “The company has said it expects to produce more than 140,000 rounds of its 10-day treatment regimen by the end of this month and anticipates it can make 1 million rounds by the end of this year. Gilead said it will be able to produce “several million” rounds of its antiviral drug next year.”

On 2 February 2022 Mackenzie Bean of Becker’s Hospital Review reported “Gilead saw $5.6B in remdesivir sales last year.

Source: https://www.beckershospitalreview.com/pharmacy/gilead-saw-5-6b-in-remdesivir-sales-last-year.html.

The profits are disturbing in consideration that remdesivir carries massive risks including mortality, multi organ failure, kidney failure, liver damage, among many other adverse events. Remdesivir does not aid recovery of covid, as stated by WHO that said it did not reduce hospitalisation time or recovery.

Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-agreement-gilead-manufacture-remdesivir

Pfizer

Pfizer, one of the main manufacturers of the covid “vaccine”, announced it is producing the drug remdesivir on behalf of patent owner Gilead Sciences that has a documented death rate of 53.1%. The announcement said,

“NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced a multi-year agreement with Gilead Sciences, Inc. to manufacture and supply Gilead’s investigational antiviral remdesivir, as one of multiple external manufacturing organizations supporting efforts to scale up supply of the investigational treatment for COVID-19. Under the terms of the agreement, Pfizer will provide contract manufacturing services at Pfizer’s McPherson, Kansas facility to manufacture and supply remdesivir for Gilead.

In March, Pfizer launched a five-point plan, which called on all members of the innovation ecosystem – from large pharmaceutical companies to the smallest of biotech companies, from government agencies to academic institutions – to commit to work together in addressing the dire COVID-19 crisis.

“From the beginning it was clear that no one company or innovation would be able to bring an end to the COVID-19 crisis. Pfizer’s agreement with Gilead is an excellent example of members of the innovation ecosystem working together to deliver medical solutions,” said Albert Bourla, Chairman and Chief Executive Officer. “Together, we are more powerful than alone. As one of the largest manufacturers of vaccines, biologics and sterile injectables, it is a privilege to offer our expertise and infrastructure to help fight this pandemic. In that spirit, we are pleased that Gilead is using our manufacturing capacity to help facilitate supply of this medicine to patients as quickly as possible.”

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Pfizer Disclosure Notice: The information contained in this release is as of August 7, 2020. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about Pfizer and Gilead’s multi-year agreement to manufacture and supply remdesivir, including its potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development; uncertainties regarding the commercial success of and the ability to realize the anticipated benefits of the manufacturing and supply agreement; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of remdesivir; uncertainties regarding the impact of COVID-19 on our business, operations and financial results; other business effects, including the effects of industry, market, economic, political or regulatory conditions; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results,” as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at http://www.sec.gov/ and www.pfizer.com.”

PFIZER MANUFACTURES VAX + REMDESIVIR

Pfizer, the first jab on the market, that was pushed through development and approval by former US President Donald Trump, now also manufacturers remdesivir on behalf of its French owner Gilead.

As such, Pfizer, that makes the jab for peoples throughout the world, now also makes the poison that has a death rate of 53.1%, for all the peoples in hospitals throughout the world.

Remdesivir was made the global covid hospital protocol, while all other drugs such as ivermectin were banned.

As such hospitals give people a poison that has a death rate of 53.1%, and when persons die, reports them as a “covid deaths”.

Deaths & Money

Dr Peterson Pierre
America’s Frontline Doctors

Outlines the bonus payments for covid and treatments:

Dr Pierre said, “so the current situation is this if you have covid and you end up in the hospital you're put on a rigid protocol and there's high mortality rate in the hospital and your family is kept in the dark as to what's happening so what's going on.

In the podcast Dr Pierre says,

The Cares Act is providing bonus payments to hospitals whenever you have a diagnosis of covid and then the center for Medicare and Medicaid Services is waiving patient rights. This is a deadly combination. So here's what happens you get a payment because:

  1. you offer a free covet test in the emergency room;

  2. you get a boost payment if you have a diagnosis of covid;

  3. you get another bonus payment if you are admitted with covid;

  4. you get another bonus payment if you're put on remdesevir;

  5. another bonus payment if you're put on a mechanical ventilator;

  6. another 20 bonus if the diagnosis on your death certificate says covid even though you may not have died from covid;

  7. and there's bonus payments to coroners.

The biden administration is literally paying hospitals to kill you

It's estimated at about a $100,000 dollars per patient is what the hospital is getting."